Evidence map›Paper›PMID 33004826›Full record

ArticleScientific reports2020

Metformin enhances protection in guinea pigs chronically infected with Mycobacterium tuberculosis.

Jessica D Haugen Frenkel, David F Ackart, Alexandra K Todd, James E DiLisio, Siana Hoffman, Samantha Tanner, Dilara Kiran, Megan Murray, Adam Chicco, Andrés Obregón-Henao and 2 more

Open access · goldFull text read
In one paragraph

Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
0.4field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Metformin improvesFrontiers in immunology · 2024
    Article
  5. Recent Advances in Host-Directed Therapies for Tuberculosis and Malaria.Frontiers in cellular and infection microbiology · 2022
    Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Lactate Metabolism and Signaling in Tuberculosis and Cancer: A Comparative Review.Frontiers in cellular and infection microbiology · 2021
    Review
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Jessica D Haugen FrenkelDepartment of Microbiology, Immunology and Pathology, Metabolism of Infectious Diseases Laboratory, Mycobacteria Research Laboratories, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO, USA.
David F AckartDepartment of Microbiology, Immunology and Pathology, Metabolism of Infectious Diseases Laboratory, Mycobacteria Research Laboratories, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO, USA.
Alexandra K ToddDepartment of Microbiology, Immunology and Pathology, Metabolism of Infectious Diseases Laboratory, Mycobacteria Research Laboratories, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO, USA.
James E DiLisioDepartment of Microbiology, Immunology and Pathology, Metabolism of Infectious Diseases Laboratory, Mycobacteria Research Laboratories, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO, USA.
Siana HoffmanDepartment of Microbiology, Immunology and Pathology, Metabolism of Infectious Diseases Laboratory, Mycobacteria Research Laboratories, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO, USA.
Samantha TannerDepartment of Microbiology, Immunology and Pathology, Metabolism of Infectious Diseases Laboratory, Mycobacteria Research Laboratories, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO, USA.
Dilara KiranDepartment of Microbiology, Immunology and Pathology, Metabolism of Infectious Diseases Laboratory, Mycobacteria Research Laboratories, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO, USA.
Megan MurrayDepartment of Global Health and Social Medicine, Harvard Medical School, Boston, MA, USA.
Adam ChiccoDepartment of Biomedical Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO, USA.
Andrés Obregón-HenaoDepartment of Microbiology, Immunology and Pathology, Metabolism of Infectious Diseases Laboratory, Mycobacteria Research Laboratories, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO, USA.
Brendan K PodellDepartment of Microbiology, Immunology and Pathology, Metabolism of Infectious Diseases Laboratory, Mycobacteria Research Laboratories, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO, USA.
Randall J BasarabaDepartment of Microbiology, Immunology and Pathology, Metabolism of Infectious Diseases Laboratory, Mycobacteria Research Laboratories, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO, USA. basaraba@colostate.edu.ORCID https://orcid.org/0000-0002-3593-5012
Colorado State University · USHarvard University · US

Funding

Metabolomics Core U19AI111224 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI MOODY, DAVID BRANCH, MURRAY, MEGAN B · 2015 to 2021
$20.4M
Veterinary Pre-Doctoral Research Scholars ProgramT32OD012201 · OD · COLORADO STATE UNIVERSITY · PI VANDEWOUDE, SUE · 2013 to 2019
$795k
Mycobacterium tuberculosis-mediated modulation of host immune cell metabolismF30OD024647 · OD · COLORADO STATE UNIVERSITY · PI KIRAN, DILARA · 2018 to 2020
$124k
NIAID NIH HHS U19 AI111224NIH HHS F30 OD024647NIH HHS F30 OD024647-01A1NIH HHS T32 OD012201
6 · The paper itself

Abstract

Tuberculosis (TB) is a chronic inflammatory disease that is often associated with alterations in systemic and cellular metabolism that resolves following successful antimicrobial drug treatment. We hypothesized that altered systemic glucose metabolism as a consequence of Mycobacterium tuberculosis (Mtb) infection, contributes to TB pathogenesis, and when normalized with anti-glycemic drugs would improve clinical outcomes. To test this hypothesis, guinea pigs were treated daily with the anti-diabetic drug metformin starting 4 weeks prior or concurrent with aerosol exposure to the H37Rv strain of Mtb. In the chronic stages of infection, Mtb infected metformin-treated animals had restored systemic insulin sensitivity but remained glucose intolerant as determined by oral glucose tolerance testing. Despite persistent glucose intolerance, metformin-treated guinea pigs had a 2.8-fold reduction in lung lesion burden and a 0.7 log decrease in CFUs. An alternative hypothesis that metformin treatment improved clinical disease by having a direct effect on immune cell energy metabolism was tested using extracellular flux analysis and flow cytometry. The proinflammatory immune response to Mtb infection in untreated guinea pigs was associated with a marked increase in energy metabolism (glycolysis and mitochondrial respiration) of peripheral blood mononuclear cells (PBMCs), which was normalized in metformin-treated guinea pigs. Moreover, both CD4

Indexed as

AnimalsCytokinesEnergy MetabolismGlucoseGlucose IntoleranceGuinea PigsHypoglycemic AgentsInsulin ResistanceLungMaleMembrane Potential, MitochondrialMetforminSuperoxidesT-LymphocytesTuberculosis, PulmonaryCytokinesGlucoseHypoglycemic AgentsMetforminSuperoxides

Identifiers

PMID33004826
PMCPMC7530990
OpenAlexW3089365745

What OpenQuestion holds

Textfull text, public
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.